| 0 (0%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.92 |
1-year : | 3.41 |
| Resists | First : | 2.5 |
Second : | 2.92 |
| Pivot price | 2.32 |
|||
| Supports | First : | 2.24 |
Second : | 2.08 |
| MAs | MA(5) : | 2.26 |
MA(20) : | 2.31 |
| MA(100) : | 2.25 |
MA(250) : | 2.27 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 55.5 |
D(3) : | 35 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 3.08 | Low : | 1.82 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ORMP ] has closed below upper band by 23.8%. Bollinger Bands are 10.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.31 - 2.32 | 2.32 - 2.33 |
| Low: | 2.23 - 2.25 | 2.25 - 2.27 |
| Close: | 2.25 - 2.28 | 2.28 - 2.31 |
Mon, 10 Nov 2025
Is ORMP still worth holding after the dip - Market Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Thu, 06 Nov 2025
How high can ORMP stock go - Quarterly Trade Summary & Trade Opportunity Analysis Reports - newser.com
Tue, 28 Oct 2025
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance
Thu, 23 Oct 2025
Oramed (NASDAQ: ORMP) posts $210M assets, plans one-time dividend; U.S. insulin trial - Stock Titan
Sat, 31 May 2025
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 41 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 13.1 (%) |
| Held by Institutions | 17.7 (%) |
| Shares Short | 209 (K) |
| Shares Short P.Month | 224 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.77 |
| Profit Margin | 0 % |
| Operating Margin | -683.7 % |
| Return on Assets (ttm) | -5 % |
| Return on Equity (ttm) | -14.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 40.9 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -3.94 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 49.2 |
| Price to Cash Flow | -6.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|